دورية أكاديمية

Sitagliptin on carotid intima-media thickness in type 2 diabetes and hyperuricemia patients: a subgroup analysis of the PROLOGUE study

التفاصيل البيبلوغرافية
العنوان: Sitagliptin on carotid intima-media thickness in type 2 diabetes and hyperuricemia patients: a subgroup analysis of the PROLOGUE study
المؤلفون: Yipin Zhao, Huawei Wang, Dazhi Ke, Wei Deng, Yingying Ji, Jiaojiao Yang, Zebin Lin, Guoxing Li, Li Xiao, Jianmin Tang, Qingwei Chen
المصدر: Therapeutic Advances in Chronic Disease, Vol 12 (2021)
بيانات النشر: SAGE Publishing, 2021.
سنة النشر: 2021
المجموعة: LCC:Therapeutics. Pharmacology
مصطلحات موضوعية: Therapeutics. Pharmacology, RM1-950
الوصف: Background and Aims: Studies have shown that dipeptidyl peptidase-4 (DDP-4) inhibitors have anti-atherosclerotic effects. However, in the PROLOGUE study, sitagliptin failed to slow the progression of carotid intima-media thickness (CIMT) relative to conventional therapy. We conducted a post hoc analysis of the PROLOGUE study and compared the effects of sitagliptin and conventional therapy on changes in CIMT in subgroups with or without hyperuricemia. Methods: The PROLOGUE study was a randomized controlled trial of 442 patients with type 2 diabetes mellitus (T2DM). Patients were randomized to receive sitagliptin added therapy or conventional therapy. Based on the serum uric acid levels of all study populations in the PROLOGUE study, we divided them into hyperuricemia subgroup ( n = 104) and non-hyperuricemia subgroup ( n = 331). The primary outcome was changed in carotid intima-media thickness (CIMT) parameters compared with baseline during the 24 months treatment period. Results: In the hyperuricemia subgroup, compared with the conventional therapy group, the changes in the mean internal carotid artery (ICA)-IMT and max ICA-IMT at 24 months were significantly lower in the sitagliptin group [−0.233 mm, 95% confidence interval (CI) (−0.419 to 0.046), p = 0.015 and −0.325 mm, 95% CI (−0.583 to −0.068), p = 0.014], although there was no significant difference in the common carotid artery CIMT. Conclusion: The results of our analysis indicated that sitagliptin attenuated the progression of CIMT than conventional therapy in T2DM and hyperuricemia patients.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2040-6231
20406223
Relation: https://doaj.org/toc/2040-6231
DOI: 10.1177/20406223211026993
URL الوصول: https://doaj.org/article/2e013b583c71463189ff7474fb8141b0
رقم الأكسشن: edsdoj.2e013b583c71463189ff7474fb8141b0
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:20406231
20406223
DOI:10.1177/20406223211026993